METHODS FOR TREATING RADIATION OR CHEMICAL INJURY
Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.
1 .- 126 . (canceled)
127 . A method of mitigating reduction, resulting from exposure to radiation, in a subject's number of endogenous hematopoietic cells, comprising administering to said subject a composition comprising adherent stromal cells (ASC), wherein the ASC are administered before said exposure, and wherein the ASC were cultured under three-dimensional culturing conditions.
128 . The method of claim 127 , wherein said ASC are administered by intramuscular injection.
129 . The method of claim 127 , wherein the origin of the ASC is placenta.
130 . The method of claim 129 , where at least 50% of the ASC are fetal cells.
131 . The method of claim 127 , wherein the origin of the ASC is selected from adipose tissue and bone marrow.
132 . The method of claim 127 , wherein said three-dimensional culturing conditions comprise culturing in a bioreactor.
133 . The method of claim 127 , wherein at least 70% of the ASC are positive for the marker CD200, as detected by flow cytometry compared to an isotype control.
134 . The method of claim 127 , wherein the ASC are administered 1 day before said exposure.
135 . A method of mitigating reduction, resulting from exposure to a chemical, in a subject's number of endogenous hematopoietic cells, comprising administering to said subject a composition comprising adherent stromal cells (ASC), wherein the ASC are administered before said exposure, and wherein the ASC were cultured under three-dimensional culturing conditions.
136 . The method of claim 135 , wherein said ASC are administered by intramuscular injection.
137 . The method of claim 135 , wherein the origin of the ASC is placenta.
138 . The method of claim 137 , where at least 50% of the ASC are fetal cells.
139 . The method of claim 135 , wherein the origin of the ASC is selected from adipose tissue and bone marrow.
140 . The method of claim 135 , wherein said three-dimensional culturing conditions comprise culturing in a bioreactor.
141 . The method of claim 135 , wherein at least 70% of the ASC are positive for the marker CD200, as detected by flow cytometry compared to an isotype control.
142 . The method of claim 135 , wherein the ASC are administered 1 day before said exposure.
143 . The method of claim 135 , wherein said chemical is a chemotherapy agent.
144 . A method of reducing a symptom associated with radiation sickness in a subject, comprising administering to said subject a composition comprising adherent stromal cells (ASC), wherein the ASC are administered before exposure to radiation, and wherein the ASC were cultured under three-dimensional culturing conditions.
145 . The method of claim 144 , wherein said symptom is selected from leukopenia, anemia, thrombocytopenia, nausea, vomiting, and diarrhea.
146 . The method of claim 144 , wherein said ASC are administered by intramuscular injection.